Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary an ovarian carcinoma cell lines

被引:22
作者
Sauer, G
Kafka, A
Grundmann, R
Kreienberg, R
Zeillinger, R
Deissler, H
机构
[1] Univ Ulm, Sch Med, Dept Obstet & Gynecol, D-89075 Ulm, Germany
[2] Univ Vienna, Sch Med, Dept Obstet & Gynecol, Vienna, Austria
关键词
multidrug resistance gene 1; polymorphism; breast cancer; ovarian cancer;
D O I
10.1016/S0304-3835(02)00232-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resistance to established drugs for cancer therapy is in many cases associated with overexpression of the multidrug resistance gene 1 (MDR-1). Regulation of basal expression of MDR-1 and mechanisms of induction as a result of exposure to cytotoxic substances are still not completely understood. Recent reports have suggested an association of the C3435T polymorphism in exon 26 of the MDR-1 gene with MDR-1 expression in duodenal mucosa cells of healthy individuals. We analyzed the C3435T and G2677T genotypes of 38 mammary and ovarian carcinoma cell lines and measured basal MDR-1 expression by real-time reverse transcriptase-polymerase chain reaction. Cell lines were classified as non-expressing or showing weak basal expression that was found to be significantly associated (six/seven versus 13/31 expressing cell lines; P = 0.0448, Fisher's exact test) with the TT genotype at position 3435 of the MDR-1 gene. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 18 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression [J].
Bargou, RC ;
Jurchott, K ;
Wagener, C ;
Bergmann, S ;
Metzner, S ;
Bommert, K ;
Mapara, MY ;
Winzer, KJ ;
Dietel, M ;
Dorken, B ;
Royer, HD .
NATURE MEDICINE, 1997, 3 (04) :447-450
[3]   MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53 [J].
CHIN, KV ;
UEDA, K ;
PASTAN, I ;
GOTTESMAN, MM .
SCIENCE, 1992, 255 (5043) :459-462
[4]  
Duhem, 1996, Oncologist, V1, P151
[5]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478
[6]  
Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
[7]  
Knutsen T, 1998, GENE CHROMOSOME CANC, V23, P44, DOI 10.1002/(SICI)1098-2264(199809)23:1<44::AID-GCC7>3.0.CO
[8]  
2-6
[9]   Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells [J].
Kusaba, H ;
Nakayama, M ;
Harada, T ;
Nomoto, M ;
Kohno, K ;
Kuwano, M ;
Wada, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 262 (03) :924-932
[10]   INTRATUMORAL HETEROGENEITY FOR AMPLIFIED GENES IN HUMAN BREAST-CARCINOMA [J].
LONN, U ;
LONN, S ;
NILSSON, B ;
STENKVIST, B .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (01) :40-45